Recursion's incoming CEO Najat Khan Recursion

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around?

In 2014, Recursion cofounder and CEO Chris Gibson promised to develop 100 drugs in 10 years, thanks to the company’s use of AI in drug discovery.

It’s been rocky. More than a decade on, Recursion still has not brought a single drug to market. Its shares have cratered 86% since its April 2021 IPO, giving it a market cap today of $2.2 billion. Earlier this year, Recursion culled half of its pipeline of drugs and in June it cut its workforce by 20%, the third round of layoffs since August 2024. And its revenue for the latest 12 months (through September 30) s

See Full Page